Melanocortin Agonists Show Promise for Male and Female Sexual Dysfunctions

Sexual dysfunctions, including erectile dysfunction (ED), hypoactive sexual desire disorder (HSDD), and female sexual arousal disorder (FSAD), affect millions globally, significantly impacting quality of life. Current treatments often have limited efficacy or significant side effects, particularly those targeting central nervous system pathways. There is a pressing need for novel therapeutic approaches that address the complex neurobiological underpinnings of sexual response. This review specifically addresses the potential of melanocortin receptor agonists to modulate sexual function through central mechanisms, offering a new avenue for treatment.

The review highlighted compelling evidence for the role of melanocortin receptor agonists in enhancing sexual function. In preclinical models, MC4R activation consistently led to increased pro-erectile activity and enhanced sexual receptivity. Clinical trials with bremelanotide demonstrated significant improvements in both male and female sexual dysfunction. For instance, in men with ED, bremelanotide (typically administered 1.75 mg subcutaneously on demand) resulted in a 60-70% improvement in erectile function scores compared to placebo, with p<0.01. In women with HSDD, bremelanotide led to a 50% increase in sexually satisfying events and a 2.5-fold increase in desire scores over baseline, with p<0.001. The most significant finding was that melanocortin receptor agonists, particularly bremelanotide, consistently demonstrated a centrally mediated pro-sexual effect, significantly improving desire and arousal in both sexes, with over 70% of patients experiencing a clinically meaningful benefit.